PharmaEssentia Innovation Research Center News and Activities

PharmaEssentia Innovation Research Center is owned by PharmaEssentia.

PharmaEssentia is a company listed under the stock ticker 6446 (TW).

PharmaEssentia has a direct presence in 3 countries.

PharmaEssentia has 4 subsidiaries including Forus Therapeutics, PharmaEssentia Innovation Research Center and PharmaEssentia Japan.

They are in:

• Biotechnology60%
• Pharmaceuticals40%

Acquisition, funding and merger involving PharmaEssentia.

• PharmaEssentia has acquired Forus Therapeutics (posted on June 18 2026).

View the org chart displaying its 5 main executives

Most searched biographies at PharmaEssentia Innovation Research Center

• Kuan-Chun Huang, Senior Director of Pharmacology and Translational...
• Erik Sampson, Director of Translational Pharmacology
• Ming-Tang Chen, Senior Director of Biologics Platform

Create your alert
to follow the executive moves at PharmaEssentia Innovation Research Center.

PharmaEssentia has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
• Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by PharmaEssentia Innovation Research Center

Social media about PharmaEssentia Innovation Research Center

• PharmaEssentia Innovation Research Center on Wikipedia, Google News & Yahoo Finance
• PharmaEssentia Innovation Research Center on LinkedIn, X (Twitter) & YouTube